
AtriCure (ATRC) Stock Forecast & Price Target
AtriCure (ATRC) Analyst Ratings
Bulls say
AtriCure is a leader in innovative surgical treatments for conditions such as atrial fibrillation and post-operative pain management, with a strong portfolio of products and a focus on sales and distribution in the United States. A potential increase in adoption through new quality metrics and growth in new verticals could lead to strong revenue growth and potential upside for the company. With a solid financial outlook and a strong position in the market, AtriCure is poised for continued success in the future.
Bears say
AtriCure is expected to experience stronger-than-expected revenue growth due to a faster 10 point penetration rate in their cardiac ablation and left atrial appendage management product lines, potentially resulting in an additional $27 million in revenue in 2027 and $55 million in 2028. Furthermore, the company anticipates further growth in international sales from the upcoming launch of their Flex-Mini and Pro-Mini products in Europe. However, softness in the UK and Germany, as well as pressure from competing procedures in the US, may hinder overall revenue growth.
This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.
AtriCure (ATRC) Analyst Forecast & Price Prediction
Start investing in AtriCure (ATRC)
Order type
Buy in
Order amount
Est. shares
0 shares